Simon-Pierre Guay
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Simon-Pierre Guay has a total of 80 co-authors. Here are the top co-authors by number of shared publications:
- Alexis Baass
Genetic Dyslipidemias Clinic of the Montreal Clinical Research Institute, Montreal
12 shared publications - Martine Paquette
Lipids, Nutrition, and Cardiovascular Prevention Clinic of the Montreal Clinical Research Institute, Montreal, Canada (Paquette and Baass)
11 shared publications - Luigi Bouchard
Department of Biochemistry and Functional Genomics, Faculty of Medicine and Health Sciences (FMHS), Université de Sherbrooke, Sherbrooke, Canada
9 shared publications Luigi Bouchard
7 shared publicationsDiane Brisson
B ECOGENE-21 Biocluster , Chicoutimi , Quebec , Canada , QC , Canada
5 shared publications- Diane Brisson
Department of Medicine, Lipidology Unit, Community Genomic Medicine Center, Université de Montréal and ECOGENE-21 Clinical and Translational Research Center, Chicoutimi, Canada (Brisson, Larouche, and Gaudet)
5 shared publications
Latest Publications
- 15 April 2026
- Published by Oxford University Press (OUP) in European Journal of Preventive Cardiology
Integration of a polygenic score into clinical risk prediction of atherosclerotic cardiovascular disease in familial hypercholesterolaemia
Aims: A high polygenic risk score for coronary artery disease (PRSCAD) has been demonstrated to be a strong and independent predictor of atherosclerotic cardiovascular disease (ASCVD) in patients with familial hypercholesterolaemia (FH). The objective was to investigate if the addition of a PRSCAD to the FH-Risk-Score enhances ASCVD risk prediction compared with the clinical score alone. Methods and results: Data from three independent cohorts of patients with FH have been analysed in this longitudinal study (n = 1438). The FH-Risk-Score equation was used to calculate the baseline 10-year ASCVD risk. A high PRSCAD was defined as a score >75th percentile. The performance of the Combined score was assessed using measures of discrimination (C statistics), calibration (predicted risk vs. observed risk), and reclassification (using a 10-year risk cutoff of 20%). Overall, the event rate was nearly doubled in individuals having a high PRSCAD [15 vs. 9%, hazard ratio (HR) 1.77, 95% confidence interval (CI) 1.20–2.61, P = 0.004]. This association was stronger in those with a genetic confirmation of FH (17 vs. 8%, HR 2.34, 95% CI 1.50–3.67, P = 0.0002). The Combined score was associated with a marginally non-significant higher C-index than the FH-Risk-Score alone (0.746–0.750, P = 0.60). The difference in C-index was significant in patients with a genetic confirmation of FH in the moderate FH-Risk-Score group (0.617–0.717, P = 0.05). Conclusion: Overall, the addition of polygenic information using PRSCAD percentiles to the FH-Risk-Score estimate did not significantly enhance ASCVD risk prediction in patients with FH. Replication efforts with larger number of individuals and incident cases are warranted.
- 15 April 2026
- Published by Oxford University Press (OUP) in European Journal of Preventive Cardiology
Integration of a polygenic score into clinical risk prediction of atherosclerotic cardiovascular disease in familial hypercholesterolaemia
Aims: A high polygenic risk score for coronary artery disease (PRSCAD) has been demonstrated to be a strong and independent predictor of atherosclerotic cardiovascular disease (ASCVD) in patients with familial hypercholesterolaemia (FH). The objective was to investigate if the addition of a PRSCAD to the FH-Risk-Score enhances ASCVD risk prediction compared with the clinical score alone. Methods and results: Data from three independent cohorts of patients with FH have been analysed in this longitudinal study (n = 1438). The FH-Risk-Score equation was used to calculate the baseline 10-year ASCVD risk. A high PRSCAD was defined as a score >75th percentile. The performance of the Combined score was assessed using measures of discrimination (C statistics), calibration (predicted risk vs. observed risk), and reclassification (using a 10-year risk cutoff of 20%). Overall, the event rate was nearly doubled in individuals having a high PRSCAD [15 vs. 9%, hazard ratio (HR) 1.77, 95% confidence interval (CI) 1.20–2.61, P = 0.004]. This association was stronger in those with a genetic confirmation of FH (17 vs. 8%, HR 2.34, 95% CI 1.50–3.67, P = 0.0002). The Combined score was associated with a marginally non-significant higher C-index than the FH-Risk-Score alone (0.746–0.750, P = 0.60). The difference in C-index was significant in patients with a genetic confirmation of FH in the moderate FH-Risk-Score group (0.617–0.717, P = 0.05). Conclusion: Overall, the addition of polygenic information using PRSCAD percentiles to the FH-Risk-Score estimate did not significantly enhance ASCVD risk prediction in patients with FH. Replication efforts with larger number of individuals and incident cases are warranted.
- 13 August 2025
- Published by Elsevier in Journal of Clinical Lipidology
- Vol. 19 (5) , 1264-1272
Extreme lipoprotein(a) is a cardiovascular risk equivalent in heterozygous familial hypercholesterolemia
- 13 August 2025
- Published by Elsevier in Journal of Clinical Lipidology
- Vol. 19 (5) , 1264-1272
Extreme lipoprotein(a) is a cardiovascular risk equivalent in heterozygous familial hypercholesterolemia
- 15 July 2025
- Published by Elsevier in Clinical Biochemistry
- Vol. 139, 110978
DNA methylation levels are independently associated with prevalence of atherosclerotic cardiovascular disease in multifactorial chylomicronemia syndrome
- 15 July 2025
- Published by Elsevier in Clinical Biochemistry
- Vol. 139, 110978
DNA methylation levels are independently associated with prevalence of atherosclerotic cardiovascular disease in multifactorial chylomicronemia syndrome
- 31 January 2025
- Published by Elsevier in Journal of Clinical Lipidology
- Vol. 19 (3) , 595-604
Polygenic risk score for coronary artery disease predicts atherosclerotic cardiovascular disease in familial hypercholesterolemia
- 31 January 2025
- Published by Elsevier in Journal of Clinical Lipidology
- Vol. 19 (3) , 595-604
Polygenic risk score for coronary artery disease predicts atherosclerotic cardiovascular disease in familial hypercholesterolemia
- 4 January 2025
- Published by Elsevier in Clinical Biochemistry
- Vol. 135, 110873
DNA methylation levels may contribute to severe hypertriglyceridemia in multifactorial chylomicronemia syndrome
- 4 January 2025
- Published by Elsevier in Clinical Biochemistry
- Vol. 135, 110873
DNA methylation levels may contribute to severe hypertriglyceridemia in multifactorial chylomicronemia syndrome
- 10 October 2024
- Published by Wiley in Journal of Gastroenterology and Hepatology
- Vol. 39 (12) , 2639-2644
Pancreatitis polygenic risk score is independently associated with all‐cause acute pancreatitis risk in the UK Biobank
Background and Aim: Acute pancreatitis (AP) is a complex disease most commonly caused by gallstones, alcohol intake, or hypertriglyceridemia. Even in subjects with hypertriglyceridemia, the risk of AP is heterogeneous. Identifying individuals with a high genetic susceptibility to AP could contribute to a better risk stratification in the clinic. This study aimed to determine if a weighted polygenic risk score (PRS) of common variants in pancreatitis susceptibility genes can independently predict all‐cause AP incidence in the general population. Methods: A weighted PRS was calculated for 484 932 individuals from the UK Biobank, including 3346 individuals who developed AP during follow‐up. The PRS included eight single nucleotide polymorphisms in known pancreatitis susceptibility genes. Results: Individuals with a pancreatitis PRS above the 90th percentile had a 1.21‐fold (1.03–1.43; P = 0.02) increased risk of AP compared with those with a pancreatitis PRS below the 90th percentile. When comparing individuals in the third tertile versus the first tertile, the risk of AP was 1.13‐fold (1.00–1.28; P = 0.06) higher. Individuals with both a high triglyceride (TG) level and a high pancreatitis PRS (third tertile) had a 2.31‐fold (1.83–2.93; P = 3.4 × 10 −12 ) increased risk of AP compared with those with a low pancreatitis PRS and a low TG level (first tertile). Overall, the association between pancreatitis PRS and incident AP was independent of baseline TG level. Conclusions: Results of this study suggest that the accumulation of common variants in pancreatitis susceptibility genes is associated with all‐cause AP incidence. Pancreatitis PRS could help clinicians identify patients who may be at higher risk of AP and who may benefit from more aggressive treatment.
- 10 October 2024
- Published by Wiley in Journal of Gastroenterology and Hepatology
- Vol. 39 (12) , 2639-2644
Pancreatitis polygenic risk score is independently associated with all‐cause acute pancreatitis risk in the UK Biobank
Background and Aim: Acute pancreatitis (AP) is a complex disease most commonly caused by gallstones, alcohol intake, or hypertriglyceridemia. Even in subjects with hypertriglyceridemia, the risk of AP is heterogeneous. Identifying individuals with a high genetic susceptibility to AP could contribute to a better risk stratification in the clinic. This study aimed to determine if a weighted polygenic risk score (PRS) of common variants in pancreatitis susceptibility genes can independently predict all‐cause AP incidence in the general population. Methods: A weighted PRS was calculated for 484 932 individuals from the UK Biobank, including 3346 individuals who developed AP during follow‐up. The PRS included eight single nucleotide polymorphisms in known pancreatitis susceptibility genes. Results: Individuals with a pancreatitis PRS above the 90th percentile had a 1.21‐fold (1.03–1.43; P = 0.02) increased risk of AP compared with those with a pancreatitis PRS below the 90th percentile. When comparing individuals in the third tertile versus the first tertile, the risk of AP was 1.13‐fold (1.00–1.28; P = 0.06) higher. Individuals with both a high triglyceride (TG) level and a high pancreatitis PRS (third tertile) had a 2.31‐fold (1.83–2.93; P = 3.4 × 10 −12 ) increased risk of AP compared with those with a low pancreatitis PRS and a low TG level (first tertile). Overall, the association between pancreatitis PRS and incident AP was independent of baseline TG level. Conclusions: Results of this study suggest that the accumulation of common variants in pancreatitis susceptibility genes is associated with all‐cause AP incidence. Pancreatitis PRS could help clinicians identify patients who may be at higher risk of AP and who may benefit from more aggressive treatment.
- 7 September 2024
- Published by The Endocrine Society in The Journal of Clinical Endocrinology & Metabolism
- Vol. 110 (6) , e1959-e1965
Predictors of Cardiovascular Disease in Individuals With Dysbetalipoproteinemia: A Prospective Study in the UK Biobank
Background Dysbetalipoproteinemia (DBL) is a disorder of remnant cholesterol metabolism associated with a severe risk of atherosclerotic cardiovascular disease (ASCVD). Objective The objective of this study was to investigate the univariate and multivariate predictors of ASCVD in individuals with DBL. Methods Data from 2,699 individuals with ε2/ε2 genotypes from the UK Biobank were included in this study. DBL was defined as having an ε2ε2 genotype with evidence of dyslipidemia, defined as total cholesterol ≥ 200 mg/dL [5.2 mmol/L] and TG ≥ 175 mg/dL [2.0 mmol/L]) or lipid-lowering therapy use (n=964). Results Age, hypertension, waist circumference and a polygenic risk score for coronary artery disease (PRSCAD) were independent predictors of ASCVD among individuals with DBL. Cumulative ASCVD-free survival was lower in the ε2/ε2 DBL group (84%) compared to the ε2/ε2 non-DBL group (94%) (pCAD ≥ median (79%) compared to those with a PRSCAD < median (89%) (p=0.001). Conclusion We show in a large prospective cohort that a PRSCAD predicts the ASCVD risk among individuals with DBL. The findings of the present study highlight the need for better risk stratification in ε2/ε2 carriers to identify high risk individuals that would need aggressive cardiovascular management despite their low apolipoprotein B value.
- 7 September 2024
- Published by The Endocrine Society in The Journal of Clinical Endocrinology & Metabolism
- Vol. 110 (6) , e1959-e1965
Predictors of Cardiovascular Disease in Individuals With Dysbetalipoproteinemia: A Prospective Study in the UK Biobank
Background Dysbetalipoproteinemia (DBL) is a disorder of remnant cholesterol metabolism associated with a severe risk of atherosclerotic cardiovascular disease (ASCVD). Objective The objective of this study was to investigate the univariate and multivariate predictors of ASCVD in individuals with DBL. Methods Data from 2,699 individuals with ε2/ε2 genotypes from the UK Biobank were included in this study. DBL was defined as having an ε2ε2 genotype with evidence of dyslipidemia, defined as total cholesterol ≥ 200 mg/dL [5.2 mmol/L] and TG ≥ 175 mg/dL [2.0 mmol/L]) or lipid-lowering therapy use (n=964). Results Age, hypertension, waist circumference and a polygenic risk score for coronary artery disease (PRSCAD) were independent predictors of ASCVD among individuals with DBL. Cumulative ASCVD-free survival was lower in the ε2/ε2 DBL group (84%) compared to the ε2/ε2 non-DBL group (94%) (pCAD ≥ median (79%) compared to those with a PRSCAD < median (89%) (p=0.001). Conclusion We show in a large prospective cohort that a PRSCAD predicts the ASCVD risk among individuals with DBL. The findings of the present study highlight the need for better risk stratification in ε2/ε2 carriers to identify high risk individuals that would need aggressive cardiovascular management despite their low apolipoprotein B value.
- 26 April 2024
- Published by Elsevier in Journal of Clinical Lipidology
- Vol. 18 (4) , e625-e630
High carrier frequency for abetalipoproteinemia and evidence of a founder variant in a French-Canadian population
- 26 April 2024
- Published by Elsevier in Journal of Clinical Lipidology
- Vol. 18 (4) , e625-e630
High carrier frequency for abetalipoproteinemia and evidence of a founder variant in a French-Canadian population
- Open Access
- 23 April 2024
- Published by The Endocrine Society in JCEM Case Reports
- Vol. 2 (5) , luae086
Two Cases of Sitosterolemia Falsely Diagnosed as Familial Hypercholesterolemia: Could Digging Deeper Have Avoided Harm?
Sitosterolemia is a rare monogenic lipid disease characterized by the excessive uptake of phytosterols and their accumulation in blood and tissues. Clinically, it can present with hypercholesterolemia and xanthomas, often causing it to be misdiagnosed as familial hypercholesterolemia (FH). The diagnosis of sitosterolemia can easily be confirmed and distinguished from FH with a sterol profile and genetic investigations. Here, we report a sibship of 2 sisters with sitosterolemia initially misdiagnosed as FH. This case report illustrates the importance of considering rare conditions, such as sitosterolemia, as a differential diagnosis in patients with hypercholesterolemia, xanthomas, and hematologic anomalies. It also emphasizes the underdiagnosis of sitosterolemia and the benefits of using sterol profiles and genetic testing in the diagnostic process to initiate the appropriate therapy and avoid harm to patients.
- 23 April 2024
- Published by The Endocrine Society in JCEM Case Reports
- Vol. 2 (5) , luae086
Open AccessTwo Cases of Sitosterolemia Falsely Diagnosed as Familial Hypercholesterolemia: Could Digging Deeper Have Avoided Harm?
Sitosterolemia is a rare monogenic lipid disease characterized by the excessive uptake of phytosterols and their accumulation in blood and tissues. Clinically, it can present with hypercholesterolemia and xanthomas, often causing it to be misdiagnosed as familial hypercholesterolemia (FH). The diagnosis of sitosterolemia can easily be confirmed and distinguished from FH with a sterol profile and genetic investigations. Here, we report a sibship of 2 sisters with sitosterolemia initially misdiagnosed as FH. This case report illustrates the importance of considering rare conditions, such as sitosterolemia, as a differential diagnosis in patients with hypercholesterolemia, xanthomas, and hematologic anomalies. It also emphasizes the underdiagnosis of sitosterolemia and the benefits of using sterol profiles and genetic testing in the diagnostic process to initiate the appropriate therapy and avoid harm to patients.
- 16 April 2024
- Published by The Endocrine Society in The Journal of Clinical Endocrinology & Metabolism
- Vol. 110 (3) , e703-e709
Prevalence of Dysbetalipoproteinemia in the UK Biobank According to Different Diagnostic Criteria
Context: Dysbetalipoproteinemia (DBL) is a multifactorial disorder that disrupts the normal metabolism of remnant lipoproteins, causing increased risk of cardiovascular disease. However, establishing a proper diagnosis is difficult, and the true prevalence of the disease in the general population remains unknown. Objective: The objectives were to study the prevalence of the disease and to validate the performance of different clinical diagnostic criteria in a large population-based cohort. Methods: This study included 453 437 participants from the UK Biobank. DBL was established in participants having an ε2ε2 genotype with mixed dyslipidemia or lipid-lowering therapy use (n = 964). The different diagnostic criteria for DBL were applied in individuals without lipid-lowering medication (n = 370 039, n = 534 DBL), to compare their performance. Results: Overall, 0.6% of participants had an ε2ε2 genotype, of which 36% were classified as DBL, for a disease prevalence of 0.2% (1:469). The prevalence of DBL was similar between the different genetic ancestries (≤0.2%). Several diagnostic criteria showed good sensitivity for the diagnosis of DBL (>90%), but they suffered from a very low positive predictive value (0.6-15.4%). Conclusion: This study reported for the first time the prevalence of DBL in the UK Biobank according to genetic ancestry. Furthermore, we provided the first external validation of different diagnostic criteria for DBL in a large population-based cohort and highlighted the fact that these criteria should not be used to diagnose DBL alone but should rather be used as a first screening step to determine which individuals may benefit from genetic testing to confirm the diagnosis.
- 16 April 2024
- Published by The Endocrine Society in The Journal of Clinical Endocrinology & Metabolism
- Vol. 110 (3) , e703-e709
Prevalence of Dysbetalipoproteinemia in the UK Biobank According to Different Diagnostic Criteria
Context: Dysbetalipoproteinemia (DBL) is a multifactorial disorder that disrupts the normal metabolism of remnant lipoproteins, causing increased risk of cardiovascular disease. However, establishing a proper diagnosis is difficult, and the true prevalence of the disease in the general population remains unknown. Objective: The objectives were to study the prevalence of the disease and to validate the performance of different clinical diagnostic criteria in a large population-based cohort. Methods: This study included 453 437 participants from the UK Biobank. DBL was established in participants having an ε2ε2 genotype with mixed dyslipidemia or lipid-lowering therapy use (n = 964). The different diagnostic criteria for DBL were applied in individuals without lipid-lowering medication (n = 370 039, n = 534 DBL), to compare their performance. Results: Overall, 0.6% of participants had an ε2ε2 genotype, of which 36% were classified as DBL, for a disease prevalence of 0.2% (1:469). The prevalence of DBL was similar between the different genetic ancestries (≤0.2%). Several diagnostic criteria showed good sensitivity for the diagnosis of DBL (>90%), but they suffered from a very low positive predictive value (0.6-15.4%). Conclusion: This study reported for the first time the prevalence of DBL in the UK Biobank according to genetic ancestry. Furthermore, we provided the first external validation of different diagnostic criteria for DBL in a large population-based cohort and highlighted the fact that these criteria should not be used to diagnose DBL alone but should rather be used as a first screening step to determine which individuals may benefit from genetic testing to confirm the diagnosis.